| Previous Close | 50.110 |
| Open | 50.160 |
| Bid | 49.810 x 400 |
| Ask | 49.810 x 500 |
| Day's Range | 49.655 - 50.160 |
| 52 Week Range | 37.380 - 51.130 |
| Volume | 547,715 |
| Avg. Volume | 6,380,525 |
| Market Cap | 86.22B |
| Beta | 1.54 |
| PE Ratio (TTM) | 51.70 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.06 (2.09%) |
| Ex-Dividend Date | 2017-07-12 |
| 1y Target Est | N/A |
- Zacks•2 days ago
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
- Market Realist•2 days ago
Analysts Raise Recommendations on Abbott Stock after 2Q17
Based on the recommendations of 19 brokerage firms in a Reuters survey, 68.0% rated Abbott Laboratories a “buy,” and 32.0% rated it a “hold.”
- Market Realist•2 days ago
Abbott Laboratories’ Updated Guidance for 2017
In 3Q17, the company's operational sales growth is expected to be in the mid-single digits. Adjusted EPS is expected to be $0.64–$0.66.
